Solifebuvir and Ledipasvir
- Generic Name
- Solifebuvir and Ledipasvir
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗丙型肝炎(简称丙肝)病毒感染。尤其适用在成年中为慢性丙肝(CHC)基因型1感染的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Breaking New Ground in Immunology & Inflammation
Kathy Dong, PharmD, leads Electra Therapeutics, developing ELA026, a first-in-class monoclonal antibody targeting SIRP for sHLH, a rare, life-threatening hyperinflammatory disease. ELA026 showed promising clinical results, achieving a 100% response rate in mHLH patients, with 100% discharge and 90% 60-day survival, suggesting rapid suppression of hyperinflammation and potential as a transformative treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath